Comparison · NCT01773187-sae
Pacritinib vs Best Available Therapy: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pacritinib vs Best Available Therapy: serious adverse events. Trial comparisons, record NCT01773187-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01773187-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.532 | 0.466 | 0.597 | wilson | |
| Risk in group 2 | 0.311 | 0.231 | 0.405 | wilson | |
| Risk difference, group 1 minus group 2 | 0.22 | 0.106 | 0.324 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.71 | 1.25 | 2.33 | log | |
| Odds ratio, group 1 over group 2 | 2.51 | 1.54 | 4.1 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Pacritinib than on Best Available Therapy | 4.54 | 3.09 | 9.42 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pacritinib | Pacritinib 400 mg QD | 117 | 220 | EG000 |
| Group 2 | Best Available Therapy | BAT includes any physician-selected treatment for primary or secondary myelofibrosis with the exclusion of JAK inhibitors (inhibitors of Janus kinases). | 33 | 106 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Time of signing informed consent through 30 days after the last study treatment.
Source ClinicalTrials.gov
Trial
- Title
- Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
- NCT number
- NCT01773187
- Phases
- PHASE3
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Interventions
- Pacritinib, Best Available Therapy
- Lead sponsor
- CTI BioPharma
- Results first posted
- 2020-09-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01773187?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01773187-sae